tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Inventiva SA

IVA
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
5.440USD
-0.110-1.98%
์ข…๊ฐ€ย 05/15, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
1.17B์‹œ๊ฐ€์ด์•ก
--P/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Inventiva SA ํšŒ์‚ฌ

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Companyโ€™s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Inventiva SA ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ IVA
ํšŒ์‚ฌ ์ด๋ฆ„Inventiva SA
์ƒ์žฅ์ผFeb 15, 2017
CEOObenshain (Andrew)
์ง์› ์ˆ˜- -
์œ ํ˜•Depository Receipt
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒ- -
์ฃผ์†Œ50 rue de Dijon
๋„์‹œDAIX
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€France
์šฐํŽธ ๋ฒˆํ˜ธ21121
์ „ํ™”33380447500
์›น์‚ฌ์ดํŠธhttps://inventivapharma.com/
์ข…๋ชฉ ์ฝ”๋“œ IVA
์ƒ์žฅ์ผFeb 15, 2017
CEOObenshain (Andrew)

Inventiva SA์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Ms. Alice Roudot-Ketelers
Ms. Alice Roudot-Ketelers
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Eric Duranson
Mr. Eric Duranson
General Counsel
General Counsel
--
--
Ms. Pascaline Clerc
Ms. Pascaline Clerc
Executive Vice President - Strategy and Corporate Affairs
Executive Vice President - Strategy and Corporate Affairs
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Ms. Alice Roudot-Ketelers
Ms. Alice Roudot-Ketelers
Chief Operating Officer
Chief Operating Officer
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Fri, May 8
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Fri, May 8
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Samsara BioCapital, LLC
2.69%
Paradigm BioCapital Advisors LP
2.07%
Deep Track Capital LP
1.64%
Adar1 Capital Management LLC
1.40%
Trails Edge Capital Partners LP
1.38%
๊ธฐํƒ€
90.83%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Samsara BioCapital, LLC
2.69%
Paradigm BioCapital Advisors LP
2.07%
Deep Track Capital LP
1.64%
Adar1 Capital Management LLC
1.40%
Trails Edge Capital Partners LP
1.38%
๊ธฐํƒ€
90.83%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Hedge Fund
9.89%
Investment Advisor/Hedge Fund
5.28%
Venture Capital
4.92%
Investment Advisor
3.97%
Private Equity
0.94%
Research Firm
0.50%
Pension Fund
0.01%
๊ธฐํƒ€
74.49%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Apr 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Apr 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2026Q1
63
49.29M
25.51%
+35.58M
2025Q4
29
15.17M
10.90%
+10.19M
2025Q3
21
4.95M
5.18%
+27.37K
2025Q2
19
4.87M
5.09%
-661.07K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Samsara BioCapital, LLC
5.19M
3.73%
--
--
Dec 31, 2025
Paradigm BioCapital Advisors LP
4.00M
2.87%
+4.00M
--
Dec 31, 2025
Deep Track Capital LP
3.16M
2.27%
+2.67M
+545.79%
Jan 23, 2026
Adar1 Capital Management LLC
2.71M
1.95%
+2.71M
--
Dec 31, 2025
Trails Edge Capital Partners LP
2.66M
1.91%
+2.66M
--
Dec 31, 2025
Millennium Management LLC
2.65M
1.91%
+2.54M
+2267.73%
Dec 31, 2025
Franklin Advisers, Inc.
2.50M
1.8%
+2.50M
--
Dec 31, 2025
SymBiosis Capital Management, LLC
2.60M
1.87%
+2.60M
--
Dec 31, 2025
UBS Financial Services, Inc.
2.64M
1.9%
+2.63M
+28881.60%
Dec 31, 2025
Caligan Partners, LP
2.00M
1.44%
+2.00M
--
Dec 31, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
์ด๋ฆ„
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
KeyAI
๎™